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ABSTRACT
Exogenous delivery of neurotrophic factors into the
cochlea of deafened animals rescues spiral ganglion
cells (SGCs) from degeneration. To be clinically
relevant for human cochlear implant candidates, the
protective effect of neurotrophins should persist after
cessation of treatment and the treated SGCs should
remain functional. In this study, the survival and
functionality of SGCs were investigated after tempo-
rary treatment with brain-derived neurotrophic factor
(BDNF). Guinea pigs in the experimental group were
deafened, and 2 weeks later, the right cochleae were
implanted with an electrode array and drug delivery
cannula. BDNF was administered to the implanted
cochleae during a 4-week period via a mini-osmotic
pump. After completion of the treatment, the osmotic
pumps were removed. Two weeks later, the animals
were killed and the survival of SGCs was analyzed. To
monitor the functionality of the auditory nerve,
electrically evoked auditory brainstem responses
(eABRs) were recorded in awake animals throughout
the experiment. BDNF treatment resulted in en-
hanced survival of SGCs 2 weeks after cessation of
the treatment and prevented the decreases in size and
circularity that are seen in the untreated contralateral
cochleae. The amplitude of the suprathreshold eABR
response in BDNF-treated animals was significantly
larger than in deafened control animals and compa-
rable to that in normal-hearing control animals. The
amplitude in the BDNF-treated group did not de-
crease significantly after cessation of treatment. The
eABR latency in BDNF-treated animals was longer
than normal and comparable to that in deafened
control animals. These morphological and functional
findings demonstrate that neurotrophic intervention
had a lasting effect, which is promising for future
clinical application of neurotrophic factors in
implanted human cochleae.
Keywords: auditory nerve, cochlear implant,
deafness, degeneration, electrically evoked auditory
brainstem response, neurotrophic factors
INTRODUCTION
A progressive loss of spiral ganglion cells (SGCs) after
loss of inner hair cells is presented in several animal
models(Spoendlin1975;WebsterandWebster1981).In
these models, electrical stimulation (Lousteau 1987;
Hartshorn et al. 1991; Leake et al. 1991) and adminis-
tration of neurotrophins (Staecker et al. 1996;M i l l e r
et al. 1997; Gillespie and Shepherd 2005;P e t t i n g i l le ta l .
2007) via a cochlear implant are effective in preventing
SGCs from degeneration after induced deafness. The
preservation of SGCs might be important since the
success of the cochlear implant is thought to be related
to the number of excitable SGCs. In the majority of
studies, neurotrophic treatment was started within the
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Shepherd 2005). It has been shown that neurotrophic
treatmentisalsoeffectiveafterdegenerationhassetin,a
condition that mimics the clinical situation (Gillespie
et al. 2004;Y a m a g a t ae ta l .2004;W i s ee ta l .2005;M i l l e r
et al. 2007; Agterberg et al. 2008; Glueckert et al. 2008).
In these studies, intracochlear infusion of neurotro-
phins by means of an osmotic pump system was started
2–6 weeks after deafening. Neurotrophic treatment
prevented SGC degeneration, but SGCs treated with
BDNF were larger than SGCs in normal cochleae and
their myelin layers were reduced (Richardson et al.
2005;S h e p h e r de ta l .2005, 2008; Agterberg et al. 2008;
Glueckert et al. 2008). These morphological changes
might reflect a suboptimal condition. Nevertheless,
SGCs treated with neurotrophins remained electrically
excitable and animals treated with neurotrophins
showed reduced thresholds of electrically evoked audi-
tory brainstem responses (eABRs) as compared to
animals in deafened control groups infused with
artificial perilymph (Shinohara et al. 2002; Yamagata
et al. 2004;S h e p h e r de ta l .2005; Maruyama et al. 2008).
An important question with respect to clinical
application of neurotrophins is whether continuous
treatment is necessary for lasting protective effects.
According to the neurotrophin hypothesis and based
upon findings in other sensory systems (Montero and
Hefti 1988; Mansour-Robaey et al. 1994), it is predicted
that cessation of neurotrophictreatment would result in
degeneration of SGCs. This prediction has been
addressed inrecent studies, which yielded contradictory
results.Gillespieetal.(2003)andShepherdetal.(2008)
reported an abnormally rapid degeneration of SGCs
after cessation of BDNF treatment. Two weeks after
cessation, the number of SGCs was not significantly
different from that in deafened, untreated cochleae. In
addition, Shepherd et al. (2008) found that chronic
electrical stimulation partially reduced the rate of SGC
loss in the basal cochlear turn, i.e., the area adjacent to
the electrode array. In contrast to these findings with
BDNF, Maruyama et al. (2008)d e m o n s t r a t e dt h a tS G C
survival and electrical responsiveness were well pre-
served aftercessation of intracochlear infusion withglial
cell line-derived neurotrophic factor (GDNF).
In the present study, we investigated the effects of
cessation of BDNF treatment. Treatment was started
2 weeks after deafening, when degeneration had set
in. Similar to Gillespie et al. (2003), we used BDNF as
neurotrophic factor, and similar to Maruyama et al.
(2008), we recorded eABRs to monitor the excitability
of the SGCs. Light microscopy was used to determine
the SGC packing density and to examine morpholog-
ical features, such as cell size and shape (circularity).
The functionality of the SGCs was assessed with the
suprathreshold amplitude (Hall 1990) and latency of
the first negative eABR peak.
METHODS
Animals and experimental design
Twenty albino female guinea pigs (strain: Dunkin
Hartley; weighing 250–350 g) were purchased from
Harlan Laboratories (Horst, The Netherlands) and
housed in the animal care facility of Utrecht University.
All animals had free access to both food and water and
were kept under standard laboratory conditions. Lights
were on between 7:00 AM and 7:00 PM. Temperature
(21°C) and humidity (60%) were kept constant.
Six guinea pigs were bilaterally deafened and
2 weeks thereafter implanted in the right cochlea with
an electrode array and cannula. Consecutively, they
received BDNF during a period of 4 weeks. After
completion of BDNF treatment, the osmotic pumps
were removed. Two weeks after BDNF treatment (i.e.,
8 weeks after deafening), these animals were killed and
processed for histology. For histological analysis, a
comparison was made between BNDF-treated and
untreated ears in the same animals; furthermore, the
histological data of BDNF-treated ears were compared
to data from normal cochleae (n=4 animals) presented
in a previous paper (Agterberg et al. 2008).
After implantation, eABRs in BDNF-treated animals
were recorded weekly to assess auditory function in
relation to electrical stimulation of the treated cochleae.
This paradigm is schematically explained in Figure 1 A.
The eABR data of the treated animals were compared
to eABRs in both normal-hearing and deafened
untreated animals. For this, we used three groups of
control animals (Fig. 1 B–D). A group of two animals
were deafened and implanted in the right cochlea with
a regular electrode array (without drug delivery
cannula) 2 weeks thereafter, and eABRs were recorded
up to more than 8 weeks after deafening (Fig. 1 B). A
second group of eight normal-hearing control animals
were implanted in the right cochlea with a regular
electrode array and eABRs were recorded weekly
(Fig. 1 C). In order to examine the effect of deafening
on the eABRs in the same animals, these animals were
deafened after 4 weeks and killed another 6 weeks later
(in one of these animals, eABRs could not be recorded
anymore in later sessions due to electrode failure). A
third group of four animals were implanted as the
second group but killed after 4 weeks while in normal-
hearing condition (Fig. 1 D). All surgical and experi-
mental procedures were approved by the Animal Care
and Use Committee of Utrecht University (DEC-UMC
# 03.04.036).
Deafening procedure
Animals were anesthetized with Domitor® (medetomi-
dine hydrochloride; 10 mg/kg, i.m.) and Ketanest-S®
((S)-ketamine; 40 mg/kg, i.m.). Before the deafening
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recorded to check hearing thresholds. Animals were
injected subcutaneously with kanamycin (400 mg/kg,
s.c.) followed (15–60 min later) by slow intravenous
infusion of furosemide (100 mg/kg, i.v.). This proce-
dure, originally reported by West et al. (1973), has
been shown to eliminate almost all cochlear hair cells
(Gillespie et al. 2003; Versnel et al. 2007). For the
intravenous infusion of furosemide, the right jugular
vein was exposed and a catheter was inserted. A
successful insertion was confirmed with withdrawal of
blood into the catheter.
Implantation and cochlear infusion
Animals were anesthetized with Domitor® (10 mg/kg,
i.m.) and Ketanest-S® (40 mg/kg, i.m.). In the control
animals the right cochleae were implanted with an
eight-electrodearray(Cochlear®,platinumringelectro-
des of 0.3 mm width, inter-electrode distance 0.75 mm).
In the experimental animals, the right cochleae were
implanted with a six-electrode array (same electrode
configuration as eight-electrode array) with drug deliv-
ery cannula (∼80 mm, ID=0.8 mm) with a tip of
∼20 mm (ID=0.12 mm; OD=0.16 mm) designed for
guinea pigs (Cochlear®), resembling the array-cannula
device described by Shepherd and Xu (2002). The
right bulla was exposed retro-auricularly and a small
hole was drilled to visualize the cochlea. The array was
inserted 3–4 mm through a cochleostomy in the basal
turn near the round window. The array cable was fixed
onto the bulla with dental cement (Ketac-Cem Aplicap,
ESPE dental supplies, Utrecht, The Netherlands) and
connected to the skull with a screw (Brown et al. 1993)
and dental cement. An Alzet® mini-osmotic pump
(model 2004; flow rate 0.25 μl/h; reservoir 200 μl) was
attached to the cannula and inserted into a subcutane-
ous pocket. The incision was closed in two layers with
Vicryl®. The cannula and the mini-osmotic pump were
filled with BDNF (PeproTech Inc., Rocky Hill, NJ, USA)
solution (100 μg/ml). This concentration was chosen
because concentrations of neurotrophins in this range
(50–100 μg/ml) have proved to be effective in several
studies (Gillespie et al. 2003, 2004; Yamagata et al. 2004;
Wise et al. 2005;M i l l e re ta l .2007; Agterberg et al. 2008;
Shepherd et al. 2008). Bovine serum albumin (1%) was
added to the BDNF solution. The pumps were incubat-
ed in sterile saline for 48 h at 37°C to guarantee a
constant flow rate at implantation.
Auditory brainstem responses
aABRs and eABRs were measured once or twice a
week in awake and freely moving animals. All
electrophysiological recordings were performed in a
sound-attenuated chamber. The aABRs and eABRs
were recorded with three stainless steel screws (8.0×
1.2 mm) inserted into the skull bone 1 cm posterior to
bregma, 2 cm anterior to bregma, and 1 cm lateral
from bregma, respectively (Mitchell et al. 1997).
Stimulus generation and signal acquisition were con-
trolled with custom-written software and a personal
computer. The stimuli were synthesized and attenuated
using a Tucker-Davis Technologies TDT3 system (mod-
ules RP2, PA5 (2x) and SA1). The responses were
amplified differentially using a Princeton Applied
Research 113 pre-amplifier (amplification 5,000; band
pass filter 0.1–10 kHz) with the posterior and anterior
screws as active and reference electrodes, respectively,
and the lateral screw as ground electrode. The
amplified signal was digitized by the TDT3 system
(module RP2) and made available for off-line analysis.
Acoustically evoked auditory brainstem responses
Broadband click stimuli consisting of monophasic
rectangular pulses (width 20 μs; interstimulus interval
99 ms) were presented in free field, using a Blaupunkt
speaker (PCxb352; 4 Ω; 30 W) positioned 10 cm above
the awake guinea pig. Threshold was defined as the
sound level at which the aABR was just visible. The click
stimuli were presented from 75 dB above the average
-4 -2 0 2 468
Time relative to deafening (weeks)
(n = 6) A
(n = 2) B
(n = 8) C
(n = 4) D
Df
CI, pump
Removal
pump
Df CI
Df CI
CI
†
†
†
†
10
Df: deafening
CI: cochlear  implantation
† : sacrificed
no eABR
BDNF and weekly eABR
weekly eABR
FIG. 1. Treatment schedule of four different animal cohorts (A–D).
A Deafened and 2 weeks later implanted and treated with BDNF; B
deafened and 2 weeks later implanted; C first implanted and 4 weeks
later deafened; D only implanted. Deafening was performed
systemically affecting both ears. Cochlear implantation (A–D) and
BDNF treatment (A) was applied to the right ear. After implantation,
eABRs were regularly recorded in each group (by electrically
stimulating the implanted right ear). For electrophysiological analy-
sis, eABRs of the BDNF-treated animals (A) were compared to eABRs
of normal-hearing animals (C before deafening, D) and to eABRs of
deafened animals (B, C after deafening). Note that data in normal-
hearing and deafened conditions were obtained in the same animals
(C). For histological analysis, the main comparison was made within
the animals treated with BDNF (A): BNDF-treated right ears were
compared to untreated left ears.
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down to threshold in 10-dB steps. Animals with a
threshold shift of 950 dB, measured 14 days after
deafening, were included as “deafened”.
Electrically evoked auditory brainstem responses
After cochlear implantation, eABRs were recorded.
Monophasic rectangular pulses generated and attenu-
ated by the TDT3 system were converted to current
pulses by a linear stimulus isolator (type A395, World
Precision Instruments). The current pulses (width
20 μs; interstimulus interval 99 ms) were presented
with alternating polarity to the most apical intra-
cochlear electrode using the lateral screw in the skull
as return electrode (monopolar eABR recordings). To
define the peaks in the eABRs, they were compared to
the peaks in the aABRs (see Fig. 2). The first positive
peak (P1) in the eABR recordings was often obscured
by the electrical artifact. In approximately half of the
animals, in at least some of the recordings, the third
positive peak (P3) was influenced by the digastric
muscle response (Hall 1990). The first negative peak
(N1) and second positive peak (P2)w e r ea l w a y sc l e a r l y
visible and not obscured by the electrical artifact or by
the digastric muscle response. Therefore, wave N1–P2
was analyzed. The N1–P2 amplitude, N1–P2 threshold,
and N1 latency were determined. The N1–P2 amplitude
was found to correlate well with SGC density (Hall
1990), and therefore, it was considered an appropriate
parameter to examine excitability of BDNF treated
SGCs. Thresholds were defined as the stimulus level
that evoked a 2.0-μV (determined with interpolation)
reproducible waveform. Stimuli were presented from
400 μA down to threshold with 2-dB steps. Higher
current levels would evoke a whisker response. The
N1–P2 amplitudes for all current levels in the experi-
mental and control animals were analyzed using
repeated-measures analysis of variance (rm ANOVA)
and t tests were used to analyze measurements at single
suprathreshold current levels.
Cessation of BDNF treatment
After 4 weeks of BDNF treatment, the animals were
anesthetized with Domitor® (10 mg/kg, i.m.) and
Ketanest-S® (40 mg/kg, i.m.). After the connection of
the cannula with the osmotic pump was checked, the
cannula was cut off at about 40 mm from the cochlea
and the osmotic pumps were removed. The open end
of the remaining cannula was sutured with Vicryl®.
The electrode array was left in place to record eABRs
after termination of the BDNF infusion. Two weeks
after cessation of BDNF treatment, the animals were
euthanized for histology.
Histology
Immediately after the final eABR measurements, the
left and right cochleae were fixed by intralabyrinthine
perfusion with a fixative consisting of 3% glutaralde-
hyde, 2% formaldehyde, 1% acrolein, and 2.5%
DMSO in 0.08 M sodium cacodylate buffer (pH 7.4)
followed by immersion in the same fixative for 3 h at
room temperature. Histological processing of the
cochleae was carried out according to our standard
protocol (De Groot et al. 1987). After decalcification
with EDTA, the cochleae were immersed in 1% OsO4
containing 1% K4Ru(CN)6 for 2 h at 4°C and then
rinsed, dehydrated, and embedded in toto in Spurr’s
low-viscosity resin. After polymerization, cochleae
were divided into two halves along a standardized
midmodiolar plane, and these were re-embedded in
fresh resin. Semithin (1 μm) sections stained with
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FIG. 2. A typical example of an aABR (top) evoked in a normal-
hearing animal, with clicks of 45 dB nSL and an eABR (bottom)
evoked with 400-μA pulses. Stimulus onset was at time 0. Note the
large stimulus artifact in the eABR before peak P1. The peak-to-peak
amplitude, N1–P2, of the eABR was measured to assess the functional
status of the auditory nerve. When the N1 and/or P2 consisted of
more than one subpeak, the first subpeak on each site of the fast
rising part of the eABR complex (indicated with the arrows) is used in
the analysis.
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microscopical evaluation and quantitative analyses.
The efficacy of the deafening procedure was
assessed, in addition to aABR thresholds, by counting
the number of remaining inner hair cells (IHCs) and
outer hair cells (OHCs) at seven different locations
along the basilar membrane at a half-turn spacing
(B1, B2, M1, M2, A1, A2, and A3; Fig. 3).
Determination of SGC packing densities was
performed as described previously (Versnel et al.
2007; Agterberg et al. 2008). SGC packing densities
were determined using digitized light microscopical
images of the spiral ganglia taken from five different
cochlear locations (B1, B2, M1, M2, and A1; Fig. 3).
Using the image analysis program NIH Image (version
1.63; US National Institutes of Health, Bethesda, MD),
the bony boundaries of Rosenthal’s canal were out-
lined and its cross-sectional area (in mm
2)w a s
calculated. The number of SGC perikarya was
counted at each location. The following populations
were included in the counts: (1) all perikarya
demonstrating the morphological determinants typi-
cal of type-I and type-II SGCs (for details, see Romand
and Romand 1984); (2) partial and complete profiles
of perikarya; and (3) perikaya with and without
evident nucleus or nucleoli. SGC packing density was
calculated by dividing the number of SGCs by the
cross-sectional area of Rosenthal’s canal and
expressed as the mean number of SGCs per square
millimeter.
The cellular features perikaryal area and cell
circularity—as a measure of perikaryal cell size and
cell shape, respectively—were selected for further
quantitative analysis. Because there is a considerable
regional variation in SGC perikaryal area within the
cochlea (Leake et al. 1999), measurements were
performed in digitized light microscopical images of
the spiral ganglion at one specific location in the basal
turn (location B2 in Fig. 3). This location was chosen,
because (1) the effect of BDNF on SGC packing
densities is most prominent in the basal turn, and (2)
it was occasionally not possible to determine SGC
packing densities for location B1, which is near to the
hookregion,duetotangentialsectioningof Rosenthal’s
canal. Only type-I SGCs with an evident nucleus were
measured. Perikaryal area was determined by outlining
the myelin sheath surrounding the type-I perikaryon.
Cellcircularityisa feature that can be measureddirectly
in NIH Image after delineating the cell’sp e r i m e t e r ,i . e . ,
the myelin sheath. It is calculated as follows: 4π×A/L
2,
where A is the area and L is the perimeter (circularity is
1 for a perfect circle and less than 1 for an imperfect
circle, e.g., 0.78 for a square).
Statistical analyses were performed using SPSS® for
Windows (version 15.0.1). SGC packing densities at
the different locations (B1–A1) were analyzed using
repeated-measures analysis of variance (rm ANOVA).
Statistical comparisons of perikaryal area and cell
circularity at location B2 were made using paired t
tests.
RESULTS
Effects of deafening procedure
Two weeks after the deafening procedure, all control
and experimental animals demonstrated threshold
shifts of 960 dB for click-evoked aABRs. This severe
hearing loss was microscopically confirmed. All hair
cells at cochlear locations B1–A1 were lost, except in
two animals (one control animal and one experimental
animal). In these animals, a few inner hair cells still
remained.
SGC packing densities
Figure4 showslight micrographsof Rosenthal’sc a n a la t
cochlear location B2, providing typical examples of
SGCs in cochleae of normal-hearing (A) and deafened
animals (B–D), and in the left untreated and right
BDNF-treatedcochleaofanexperimentalanimal(E,F).
In the normal cochlea, Rosenthal’s canal contained the
full complement of SGCs and nerve fibers embedded in
a matrix consisting of vascularized connective tissue
(Fig. 4A). Two weeks after deafening, the cellular
distribution within the spiral ganglia was similar to
normal (Fig. 4B). Figure 4C illustrates the dramatic loss
of SGCs in the left cochlea of a control animal that was
examined 6 weeks after deafening. In the right cochlea,
which was electrically stimulated for short periods with
the purpose to record eABRs, the loss of SGCs was
equally dramatic (Fig. 4D). This indicates that brief
electrical stimulation did not prevent degeneration.
Eight weeks after deafening, a dramatic loss of SGCs
B1
n. VIII
A3
A2
A1
M2
B2
M1
1.5 A3
3.5 A2
5.5 A1
7.5 M2
9.5 M1
12.5 B2
16.5 B1
Location         Distance from 
apex (mm)
FIG. 3. Light micrograph of a midmodiolar section (1 μm) of a
normal guinea pig cochlea showing the different locations at which
SGCs were examined. The distance from the apex of the locations B1
through A3 are specified in the table. n. VIII cochlear nerve.
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BDNF-treated animal (Fig. 4E). The surviving SGCs had
lost their characteristic ovoid shape and, instead, had
acquired a more elongated or dendritic appearance. In
the BDNF-treated cochlea of the same animal, 2 weeks
after cessation of BDNF treatment, no signs of degener-
ation were observed (Fig. 4F). The amount of SGCs was
comparabletothatinthenormalcochlea,andtheSGCs
kept their characteristic ovoid shape.
Figure 5 compares SGC packing densities, at
cochlear locations from B1 through A1, averaged
across animals (n=6), in BDNF-treated cochleae with
those in the untreated contralateral cochleae and with
normal data (dashed lines). The data confirm the
result shown in Figure 4E, F. SGC packing densities in
BDNF-treated cochleae were normal at locations B1–
M2 and by a factor 3 larger than those in untreated
cochleae (rm ANOVA: F(1, 5)=65, pG0.001).
FIG. 4. Light micrographs of Rosenthal’s canal at location B2
(upper basal turn) with the distribution of SGCs (arrowheads) and
nerve fibers (arrows). SGCs and nerve fibers in the spiral ganglion
from A a normal cochlea, B a cochlea 2 weeks after deafening, C a
left cochlea 6 weeks after deafening, D the right implanted cochlea
from the same animal as in (C), E the left cochlea of an animal
8 weeks after deafening, and F the right implanted cochlea treated
with BDNF from the same animal as in (E) (2 weeks after cessation of
treatment).
360 AGTERBERG ET AL.: Cessation of Neurotrophic TreatmentIt is possible that electrical stimulation during eABR
recordings contributed to the enhanced survival of
SGCs (cf. Mitchell et al. 1997). Therefore, within
untreated deafened animals, we compared the SGC
packing densities in the stimulated implanted ears (see
example in Fig. 4D) to those in the nonstimulated
contralateral ears (see Fig. 4C). There were no statisti-
cally significant differences in SGC packing density
between stimulated implanted ears and nonstimulated
contralateral ears (rm ANOVA: F(1, 5)=3.2, p90.1).
Perikaryal area and circularity
Figure 6 shows the mean values of the perikaryal area
(Fig. 6A) and circularity (Fig. 6B) of SGCs at cochlear
location B2. The perikaryal area of BDNF-treated
SGCs was larger than that of SGCs in the untreated
contralateral cochleae with a difference of 25%
(paired t test, pG0.05). Circularity of BDNF-treated
SGCs was larger than that of SGCs in the contralateral
cochleae with a difference of 8% (paired t test, pG
0.05). Perikaryal area and circularity of BDNF-treated
SGCs were not statistically different from perikaryal
area and circularity of SGCs in normal-hearing guinea
pigs. SGCs in the implanted cochleae that were
electrically stimulated during eABR recordings were
larger than those in the unstimulated contralateral
ears (data not shown, 12%, paired t test, pG0.05).
There was no significant difference in circularity of
SGCs in the implanted ears as compared to the
unstimulated contralateral ears (paired t test, p90.2).
Electronically evoked auditory brainstem
responses
Figure 7 shows eABR recordings in two animals (top
and middle row) in the normal (A, C) and deafened
(B, D) condition. The decrease in N1–P2 amplitude
after deafening was prominent in the recordings after
deafening for current levels of 318 and 400 μA. The
thresholds in these examples did not change after
deafening. The P3 of the eABR recordings in gp-sp02
(A, B) at stimulus intensities of 400 and 318 μAw a s
influenced by the digastric muscle response (arrow).
Figure 7E, F depicts eABR recordings in gp-mr02 after
4 weeks of BDNF treatment (i.e., 6 weeks after
deafening) and 2 weeks after cessation of BDNF
treatment (i.e., 8 weeks after deafening). The N1–P2
amplitude did not decrease after cessation of BDNF
treatment, and the threshold did not change.
eABR amplitude
Figure 8 shows the input–output curves of eABRs in
normal-hearing animals, animals 6 weeks after deaf-
ening, animals after 4 weeks of BDNF treatment (i.e.,
6 weeks after deafening), and animals 2 weeks after
cessation of BDNF treatment. The amplitude of the
N1–P2 complex was decreased in deafened animals
for stimulus intensities of 252 μA (unpaired t test, pG
0.05), 318 μA (unpaired t test, pG0.01), and 400 μA
(unpaired t test, pG0.001) as compared to the
amplitude in normal-hearing animals. At lower stim-
ulus currents (100–200 μA), the amplitude differ-
ences were smaller and not significant (p90.2). The
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FIG. 5. Mean SGC packing densities at cochlear locations B1, B2,
M1, M2, and A1 in the left (untreated) and right (BDNF-treated)
cochlea of deafened animals (n=6). Dashed lines represent SGC
densities at locations B1–A1 in normal cochleae. Error bars: SEM.
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FIG. 6. Perikaryal area (A) and cell circularity (B) of SGCs in left
untreated versus BDNF-treated cochleae. Only SGCs with an
obvious nucleus in basal location B2 were included. Data were
obtained by averaging all individual SGC measurements within one
spiral ganglion, followed by averaging across cochleae. Dashed lines
represent measurements in normal-hearing animals. n the number of
SGCs measured. Error bars: SEM. *pG0.05.
AGTERBERG ET AL.: Cessation of Neurotrophic Treatment 361amplitudes in BDNF-treated animals were near the
amplitudes found in normal-hearing animals (un-
paired t test, p90.4) and significantly larger than in
the deafened animals for stimulus intensities of
318 μA (unpaired t test, pG0.05) and 400 μA (un-
paired t test, pG0.01). There was no significant change
in amplitude at any current level after cessation of
treatment (paired t test, p90.1).
Figure 9 shows the mean time course of eABR
amplitudes elicited with 400 μA pulses for the BDNF-
treated animals and the control animals. In both
groups, amplitudes were increasing during the first 2–
3 weeks after implantation. The control animals
showed a gradual and significant decrease in ampli-
tude after deafening. Six weeks after deafening, the
amplitude was at 60% of the original value. The
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FIG. 7. Recordings of representative eABRs evoked with current
pulses of 400 μA down to below threshold in two control animals
(gp-sp02 and gp-ju02) and one experimental animal (gp-mr02).
Recordings of two control animals are depicted to illustrate the inter-
animal variability. A, C Recorded in normal-hearing condition, prior
to deafening; B, D recorded 5 and 6 weeks after deafening,
respectively. E Recorded after 4 weeks of BDNF treatment and F
2 weeks after cessation of the treatment. T indicates the threshold of
wave N1–P2. The arrow indicates the peak that probably reflects the
digastric muscle response.
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of BDNF treatment (p90.6). The eABR recordings in
these animals also yielded threshold and latency data
which will be described in the following sections.
eABR threshold
Figure10showsamoderatedecreaseineABRthreshold
in the control group during the first weeks after
implantation (rm ANOVA: pG0.05). The threshold in
these animals did not change significantly during
6 weeks after deafening (rm ANOVA: p90.5). The eABR
threshold significantly decreased over time in the group
temporarily treated with BDNF (rm ANOVA: pG0.01).
AftercessationofBDNFtreatment,theeABRthresholds
did not demonstrate any significant changes.
eABR latency
Figure 11 shows the time course of N1 latencies of
eABRs to 400-μA pulses for both the BDNF-treated
and control animals. Deafening caused a prominent
latency change, which occurred mostly in the first
2 weeks: first a decrease and then an increase. In the
deafened condition, latencies were longer by about
0.15 ms than in the normal condition (paired t test
6 weeks after deafening versus normal, pG0.001). In
general, animals treated with BDNF demonstrated
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FIG. 8. Mean input–output functions of eABRs recorded in control
animals before deafening (normal hearing, n=12) and 6 weeks after
deafening (n=9), and in the experimental animals immediately after
4 weeks of BDNF treatment (n=5) and 2 weeks after cessation of
BDNF treatment (n=5). Error bars: SEM. *pG0.05 indicates statistical
significant difference between the untreated animals 6 weeks after
deafening and each of the other data points.
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FIG. 9. Mean N1–P2 amplitudes of eABRs recorded to 400-μA
pulses in control (n=7) and experimental (n=5) animals. The control
animals were implanted at −4 weeks and deafened at 0 weeks. The
experimental animals were deafened at 0 weeks and implanted in
the right cochlea at 2 weeks. Following implantation, the experi-
mental animals received BDNF for a 4-week period (indicated with a
horizontal bold bar). Error bars: SEM.
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FIG. 11. Mean N1 latencies of eABRs evoked with 400-μA pulses,
observed in control (n=7) and experimental (n=5) animals. The
experimental animals were deafened at 0 weeks and implanted in
the right cochlea at 2 weeks. Following implantation, the experi-
mental animals received BDNF for a 4-week period (indicated with a
horizontal bold bar). Statistical analyses within each group are not
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period, the variance among animals was large, with
some animals having longer latencies (as compared to
the deafened controls) and others having shorter
latencies (as compared to controls 1 week after
deafening). After cessation of treatment, all animals
had longer latencies, very similar to deafened controls
and significantly longer than normal-hearing controls
(unpaired t test, pG0.01). Statistical analysis of the
latencies performed on all animals (as in Fig. 8)
showed similar outcomes.
DISCUSSION
The present study showed that temporary treatment
with BDNF prevented degeneration of SGCs, which is
commonly observed after inner hair cell loss in
ototoxically deafened guinea pigs (Ylikoski et al.
1974; Webster and Webster 1981). Two weeks after
cessation of BDNF treatment, SGC packing densities
were as in cochleae of normal-hearing guinea pigs
and three times greater than in the untreated
contralateral cochleae (Fig. 5). Amplitudes of eABR
wave N1–P2 in BDNF-treated animals were compara-
ble to those in normal-hearing animals and larger
than in untreated deafened animals.
Preservation of SGCs after cessation of treatment
In contrast to our findings, Gillespie et al. (2003) and
Shepherd et al. (2008) reported that the number of
SGCs was similar to that in untreated, contralateral
cochleae, already 2 weeks after withdrawal of BDNF.
In addition, Shepherd et al. (2008) reported that
electrical stimulation after BDNF treatment only
partially prevented degeneration of SGCs in the basal
turn. The differences between their studies and our
study that may contribute to the contrasting results
are: (1) recordings of the eABRs, (2) concentration of
BDNF, (3) method of cessation of BDNF treatment,
and (4) period of deafness before the start of the
neurotrophic treatment.
1. We recorded eABRs, while Gillespie et al. (2003)
did not. The brief (∼20 min) stimulation at
10 pulses/s twice per week might have provided
some neurotrophic support enhancing the survival
of SGCs after cessation of BDNF treatment. Pre-
vention of SGC degeneration in deafened animals,
solely due to eABR recordings, has been previously
reported (Miller and Altschuler 1995; Mitchell et
al. 1997). Chikar et al. (2008) found enhanced
SGC survival 12 weeks after a single inoculation
with an adenovirus suspension encoding for BDNF
(Ad.BDNF), and they argued that eABR recordings
contributed to this. Maruyama et al. (2008) dem-
onstrated enhanced survival of SGCs after cessation
of intracochlear infusion of GDNF. Similar to our
study, brief electrical stimulation during eABR
recordings was provided once a week. A synergistic
effect of BDNF treatment in combination with
chronic electrical stimulation has also been
reported (Kanzaki et al. 2002; Shepherd et al.
2005; Song et al. 2009), indicating that synergy of
eABR recordings and BDNF treatment might be
present. Finally, we found that eABRs prevented
decrease of SGC size, which might indicate some
trophic effect (Richardson et al. 2005). Based on
the data described above, one would argue that
eABR recordings explain the discrepancy between
our study and their studies. However, the following
arguments point against this effect of eABRs. First,
our results demonstrated that eABR recordings
alone did not affect the SGC packing density.
Second, Shepherd et al. (2008)r e p o r t e dt h a t
electrical stimulation only prevented SGC degen-
eration in the basal cochlear turn, whereas we
found persistent survival in all cochlear locations
examined (2.5 cochlear turns).
2. In our study, a BDNF concentration of 100 μg/ml
was chosen, and in their studies 62.5 μg/ml. Because
concentrations in the range of 50–100 μg/ml are
equally effective, as judged immediately after
treatment (Gillespie et al. 2004; Yamagata et al.
2004; Wise et al. 2005; Miller et al. 2007; Agterberg
et al. 2008), and even lower concentrations have
been reported to be effective (50 ng/ml; Miller et
al. 1997), it is unlikely that differences in concen-
tration may explain the conflicting results.
3. We cut off the cannula to stop the BDNF flow
exactly 4 weeks after the start of the treatment. It
cannot be excluded that residual BDNF in the
cannula (∼10 μl) could diffuse in the cochlea
resulting in a lasting effect on SGC survival. This
seems to be unlikely since the tip of the cannula
(0.12 mm) was very small, and we observed that the
tip was obstructed when we killed the animals for
histology (2 weeks after the flow rate stopped). In
their studies, the mini-osmotic pumps were not
removed after cessation of BDNF treatment. Deliv-
ery of BDNF stopped 4 weeks after implantation
because the lifetime of the pump was limited to
4 weeks. However, an empty reservoir of the
osmotic pump will result in an increased osmotic
pressure, which might eventually cause damage to
pump and cannula. The effect on the cochlea is
hard to assess, but one cannot exclude for instance
withdrawal or contamination of perilymph jeopar-
dizing the condition of the SGCs.
4. In their studies, BDNF treatment started 5 days after
deafening, which is before loss of SGCs, whereas in
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degeneration has started (Versnel et al. 2007).
Considering the four issues addressed above, we
propose eABR recordings as the most likely candidate
to explain the discrepancy between our data and
those of Gillespie et al. (2003). However, we cannot
exclude any of the other three arguments.
Although the lasting effect of the neurotrophic
treatment is evident in the present study (Fig. 5), this
effect is only evaluated 2 weeks after cessation.
Degeneration after deafening is not pronounced after
2 weeks (∼80% of normal density, Versnel et al. 2007).
Also the decline in eABR amplitude after deafening is
rather slow (Fig. 9). Therefore, to investigate, both
histologically and functionally, whether degeneration
after cessation of BDNF treatment is slower than
degeneration after deafening without intervention, it
is important to apply longer periods of survival.
Morphology of SGCs after cessation of BDNF
treatment
Immediately after BDNF treatment, SGCs are larger
than SGCs in normal-hearing animals (Shepherd et al.
2005; Richardson et al. 2005; Agterberg et al. 2008). We
found that 2 weeks after cessation SGCs had a normal
size (while larger than in the untreated contralateral
cochlea).Thisimpliesthattheperikaryalareadecreased
after cessation from larger-than-normal, to normal
values. The question remains if the back-to-normal area
is an indication of a normal condition. On the other
hand,thedecreaseofcellsizefollowingcessationmaybe
an early indication for initiation of a degenerative
process (Staecker et al. 1996;L e a k ee ta l .1999;
Agterberg et al. 2008). To answer this last question, the
survival of SGCs needs to be investigated for longer
periods after cessation of the neurotrophic treatment.
eABR amplitudes
We applied suprathreshold amplitudes as a measure of
excitability of the auditory nerve, since the amplitude
reflects the summed neural firings of a large popula-
tion of SGCs, whereas the more commonly used
parameter threshold reflects the function of only the
most sensitive auditory nerve fibers. Indeed, at least in
case of monopolar stimulation, the amplitude of early
eABR waves has been found to correlate well with the
number of SGCs (Smith and Simmons 1983;H a l l
1990) whereas correlations between eABR threshold
and nerve survival were weak (Smith and Simmons
1983). Note that for bipolar stimulation a better
correlation was found for threshold measures than
for amplitude measures (Miller et al. 1994).
The normal eABR amplitude in BDNF-treated ani-
malsindicatesthattreatedSGCsrespondedasnormalto
electric stimuli. It should be noted that the amplitude
after deafening was smaller, probably because less SGCs
were present, thus implicating that the remaining
untreated cells responded normally. Our data agree
with the results of Maruyama et al. (2008) who reported
that amplitudes in neurotrophically treated animals
were larger than in untreated animals and were stable
after cessation of the treatment.
A decrease of eABR threshold was found the first
weeks after implantation in the normal-hearing con-
dition. This might be due to mechanisms as tissue
growth around the electrodes and recovery from
insertion-induced trauma (Su et al. 2008). We assume
the threshold decrease found in the animals treated
with BDNF was rather due to these mechanisms than
to the preservation of SGCs mediated by the BDNF.
Our threshold data do not agree with other inves-
tigators who reported lower thresholds (by 4–9d B )i n
deafened guinea pigs treated with neurotrophins as
compared to deafened and untreated guinea pigs
(Shinohara et al. 2002; Yamagata et al. 2004;S h e p h e r d
et al. 2005;C h i k a re ta l .2008; Maruyama et al. 2008). In
these studies, the decrease in eABR threshold corre-
sponded with enhanced survival of SGCs after neuro-
trophic treatment. Contrary to these studies, in which
eABR thresholds were often assessed on the basis of
visual inspection of peak 3 and recordings were
performed in anesthetized animals, we assessed the
eABR threshold on the basis of interpolation of N1–P2
amplitudes and we recorded in awake animals. Possibly,
the difference in peaks analyzed explains the different
thresholddataasMitchelletal.(1997) reported that the
threshold of the late eABR peaks in deafened animals
decreasedovertime,whileearlypeak thresholdsdid not
significantly change. Further, the state of the animal
plays a role in that the threshold increases with
anesthesia as was found for aABRs in mice by Van Looij
et al. (2004). The effects of anesthesia may be nonlinear
and differ between various experimental conditions.
eABR latencies
The eABR N1 latencies were longer in deafened and
BDNF-treated animals than in normal-hearing animals
(Fig. 11). The initial latency decrease after deafening
m a yb ec a u s e db yd e g e n e r a t i o no fd e n d r i t e sa n dal o s s
ofspontaneousactivity,andthesubsequentincreasecan
be attributed to a reduction of the number of myelin
layers, which follows dendritic degeneration (Leake
and Hradek 1988). The BDNF-treated nerve cells have
a similar degree of myelination as untreated cells
(Agterberg et al. 2008; Glueckert et al. 2008), and this
might explain the similar latencies of BDNF-treated and
untreated animals.
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Our results demonstrate that SGC survival in deafened
animals, in both morphological and functional sense, is
not reduced after cessation of intracochlear application
of BDNF. The enhanced survival of SGCs is a promising
finding for cochlear implant candidates since there are
currently no potential methods available to provide
neurotrophins for periods that extend the order of
months. Lifelong neurotrophic treatment via an osmot-
ic pump is not clinically preferable because of repetitive
invasivemanipulationsneededtoreplacethepumpand
high infection risks.
Before neurotrophic treatment can be considered
a clinical option, it is important to investigate in
animal studies whether neurotrophic treatment does
actually improve the sound perception performance
with a cochlear implant. A major topic that needs to
be further explored is the assumption that more and
better functioning SGCs would result in a better
performance of cochlear implant users. Alternative
to this hypothesis, it might be that a minimum
number of SGCs is required for electrical hearing,
and that an increase above this minimum would have
little functional impact (Blamey 1997). Clinical data
do not support the assumption that more SGCs would
lead to a better behavioral performance (Nadol et al.
2001; Khan et al. 2005; Fayad and Linthicum 2006;
Nadol and Eddington 2006). These data indicate that
abnormalities in the central auditory pathways are at
least as important as SGC survival in limiting the
performance of cochlear implant users (Nadol et al.
2001). Furthermore, the overall performance of
cochlear implant users improves markedly within
weeks as a result of implant use, confirming the role
of the central auditory system and its plasticity (Kral
and Eggermont 2007). Still, we, and others, think that
it is unlikely that SGC loss does not affect the
performance with a cochlear implant and that the
human data sets are still too limited to conclude that
the extent of SGC survival does not influence cochlear
implant performance (Khan et al. 2005; Leake et al.
2008). Moreover, it should be considered that with
improved cochlear implant technology the number of
SGCs might become more important (Green et al.
2008).
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